Pipeline Overview

Pipeline Overview

Rexgenero is developing three products in clinical trials REX-001, REX-002 and REX-003, which are all potential treatments for CLI in both diabetic and non-diabetic patients. In addition, the company is studying the use of cellular therapies in other cardiovascular and neurological indications with earlier stage products.